Sign In
Buy AVTX
$18.25
-1.14 (-5.88%)
At Close: Jul 31, 2026
Avalo Therapeutics to Present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference
08:00am, Tuesday, 04'th Feb 2025
WAYNE, Pa. and ROCKVILLE, Md. , Feb. 04, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, toda
Avalo Therapeutics Appoints Jennifer Riley as Chief Strategy Officer
07:00am, Thursday, 02'nd Jan 2025
WAYNE, Pa. and ROCKVILLE, Md., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today
Avalo Therapeutics Receives $69.4 Million in Proceeds from the Full Exercise of Private Placement Warrants
07:00am, Tuesday, 12'th Nov 2024
WAYNE, Pa. and ROCKVILLE, Md., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today
Avalo Therapeutics to Present at Upcoming Investor Conferences
07:00am, Monday, 11'th Nov 2024
WAYNE, Pa. and ROCKVILLE, Md., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today
Avalo Announces First Patient Dosed in Phase 2 LOTUS Trial of AVTX-009 for the Treatment of Hidradenitis Suppurativa
07:00am, Tuesday, 08'th Oct 2024
WAYNE, Pa. and ROCKVILLE, Md., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), today announced that the first patient has been dosed in the Company's Phase 2 LOTUS trial of
The 3 Best Personalized Nutrition Stocks to Buy Now
10:57am, Wednesday, 24'th Jul 2024
It could be quite beneficial to invest in personalized nutrition stocks for this month in July. Some applications in the personalized nutrition market are now using artificial intelligence and machine
Avalo Therapeutics Announces Appointment of Dr. Mittie Doyle as Chief Medical Officer
07:00am, Tuesday, 16'th Jul 2024
WAYNE, Pa. and ROCKVILLE, Md., July 16, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) today announced that Mittie Doyle, MD, FACR has joined the Company as its Chief Medical Officer
Avalo Therapeutics Announces Active IND for AVTX-009, an anti-IL-1β mAb, to Treat Hidradenitis Suppurativa
07:00am, Tuesday, 09'th Jul 2024
WAYNE, Pa. and ROCKVILLE, Md., July 09, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) today announced that the Investigational New Drug (IND) for AVTX-009, an anti-IL-1β monoclonal
Avalo Therapeutics Announces Appointment of Paul Varki as Chief Legal Officer
04:01pm, Monday, 24'th Jun 2024
WAYNE, Pa. and ROCKVILLE, Md., June 24, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) today announced that Paul Varki has joined the Company as its Chief Legal Officer.
Avalo to Present at the Oppenheimer Novel Targets in Immunology Summit
07:30am, Monday, 17'th Jun 2024
WAYNE, Pa. and ROCKVILLE, Md., June 17, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) announced today that Garry A. Neil, M.D., Chief Executive Officer and Chairman of the Board, wi
Is Avalo Therapeutics (AVTX) Stock Outpacing Its Medical Peers This Year?
10:40am, Wednesday, 22'nd May 2024
Here is how Avalo Therapeutics, Inc. (AVTX) and Annexon, Inc. (ANNX) have performed compared to their sector so far this year.
Avalo Reports First Quarter 2024 Financial Results and Provides Business Updates
07:30am, Monday, 13'th May 2024
WAYNE, Pa. and ROCKVILLE, Md., May 13, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), today announced business updates and financial results for the first quarter of 2024.
Avalo Therapeutics (AVTX) Surges 270% in a Week: Here's Why
12:31pm, Tuesday, 02'nd Apr 2024
Avalo (AVTX) surges on adding a new pipeline drug, which has its origins at Eli Lilly. Alongside the acquisition, it also secured funding to continue operations beyond 2027.
Avalo Therapeutics Appoints Biotech Leaders to Board of Directors
07:00am, Tuesday, 02'nd Apr 2024
WAYNE, Pa. and ROCKVILLE, Md., April 02, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) today announced the addition of multiple biotech leaders to its Board of Directors. The Avalo
Avalo Therapeutics (AVTX) stock slips after earnings: buy the dip?
06:02am, Monday, 01'st Apr 2024
Avalo Therapeutics (AVTX) stock price nosedived on Monday after the company published relatively weak financial results. It tumbled by over 23.5% in the pre-market session and reached a low of $16.60.
